{
    "nct_id": "NCT03575871",
    "official_title": "A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
    "inclusion_criteria": "* 12 years of age or older with a minimum body weight of 40 kg\n* Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS severity 4)\n* Recent history of inadequate response or inability to tolerate topical AD treatments or require systemic treatments for AD control\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study\n* Prior treatment with JAK inhibitors\n* Other active nonAD inflammatory skin diseases or conditions affecting skin\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator\n* Pregnant or breastfeeding women, or women of childbearing potential who are unwilling to use contraception",
    "miscellaneous_criteria": ""
}